Neoplasms, Neuroepithelial  >>  Cilcane (cilengitide)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

8 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cilcane (cilengitide) / Iceni Pharma
EMD 121974-009, NCT00093964: Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor)

Completed
2a
81
US
Cilengitide 500 mg, EMD 121974, Cilengitide 2000 mg
EMD Serono
Glioblastoma Multiforme
10/05
10/10
NCT00112866: Cilengitide in Treating Patients Who Are Undergoing Surgery for Recurrent or Progressive Glioblastoma Multiforme

Terminated
2
30
US
cilengitide, EMD 121974, therapeutic conventional surgery, pharmacological study, pharmacological studies, laboratory biomarker analysis
National Cancer Institute (NCI)
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
12/08
03/09
NCT00679354: Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy

Completed
2
30
Canada, US
cilengitide, EMD 121974, laboratory biomarker analysis, pharmacological study, pharmacological studies
National Cancer Institute (NCI)
Childhood High-grade Cerebellar Astrocytoma, Childhood High-grade Cerebral Astrocytoma, Recurrent Childhood Anaplastic Astrocytoma, Recurrent Childhood Anaplastic Oligoastrocytoma, Recurrent Childhood Anaplastic Oligodendroglioma, Recurrent Childhood Brain Tumor, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Glioblastoma, Recurrent Childhood Visual Pathway and Hypothalamic Glioma
10/10
07/11
NCT01044225 / 2009-012324-83: Effect of Radiation Therapy Plus Temozolomide Combined With Cilengitide or Cetuximab on the 1-year Overall Survival of Patients With Newly Diagnosed MGMT-promoter Unmethylated Glioblastoma

Terminated
2
12
Europe
Cetuximab, Cilengitide EMD 121974
Bart Neyns
Glioblastoma
09/11
09/11
NCT00085254: Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Completed
2
112
US
cilengitide, EMD 121974, temozolomide, SCH 52365, Temodal, Temodar, TMZ, radiation therapy, irradiation, radiotherapy, therapy, radiation, laboratory biomarker analysis, pharmacological study, pharmacological studies
National Cancer Institute (NCI)
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
11/12
11/12
CORE, NCT00813943: Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status

Completed
2
265
US, Europe
Cilengitide (2-times weekly), cilengitide (5-times weekly), Temozolomide, Radiotherapy
EMD Serono, Merck KGaA, Darmstadt, Germany
Glioblastoma
02/13
08/13
NCT01517776 / 2009-011898-33: Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Adolescents

Terminated
2
28
Europe
Cilengitide, EMD 121974, Temozolomide, Temodal
Martin-Luther-Universität Halle-Wittenberg, Merck KGaA, Darmstadt, Germany
Gliomas
03/14
04/14
NCT01782976: Ph II Cilengitide Plus Bevacizumab for Recurrent Glioblastoma (GBM)

Withdrawn
2
0
NA
Cilengitide, EMD 121974, Bevacizumab, Avastin, Anti-VEGF monoclonal antibody, rhuMAb-VEGF, Questionnaire, Survey
M.D. Anderson Cancer Center, Brain Tumor Trials Collaborative, EMD Serono
Glioblastoma
06/17
 

Download Options